Gennex Laboratories Limited
BSE: GENNEX
Prev Close
11.78
Open Price
11.99
Volume
365,473
Today Low / High
11.91 / 12.5
52 WK Low / High
11.15 / 19
Range
12 - 13
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 12.45, reflecting a change of 0.67 (5.68761%). The expected target range on the BSE is 12 - 13. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Gennex Laboratories Limited Graph
Gennex Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Gennex Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 12.45, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 12.45 | 12.57 | 11.32 - 13.83 |
| 12.70 | 10.16 - 15.24 | ||
| 12.82 | 8.98 - 16.67 | ||
| Bearish Scenario | 12.45 | 12.33 | 11.09 - 13.56 |
| 12.20 | 9.76 - 14.64 | ||
| 12.08 | 8.45 - 15.70 |
Overview of Gennex Laboratories Limited
ISIN
INE509C01026
Industry
Medical - Pharmaceuticals
Vol.Avg
451,286
Market Cap
2,765,767,680
Last Dividend
0
Official Website
IPO Date
2001-04-26
DCF Diff
19.08
DCF
-7
Financial Ratios Every Investor Needs
Stock Dividend of GENNEX
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2001-09-10 | September 10, 01 | 0.095402 | 0.9998 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 137.90 Cr | 107.42 Cr | 30.48 Cr | 0.2210 | 0.00 Cr | 0.00 Cr | 14.73 Cr | 16.12 Cr | 0.76 | 27.15 Cr | 0.1169 |
| 2024-03-31 | 86.71 Cr | 59.01 Cr | 27.70 Cr | 0.3194 | 0.00 Cr | 0.54 Cr | 14.66 Cr | 13.18 Cr | 0.67 | 21.94 Cr | 0.1519 |
| 2023-03-31 | 65.60 Cr | 39.91 Cr | 25.69 Cr | 0.3916 | 0.00 Cr | 0.51 Cr | 3.81 Cr | 4.92 Cr | 0.34 | 8.65 Cr | 0.0750 |
| 2022-03-31 | 61.18 Cr | 38.67 Cr | 22.50 Cr | 0.3679 | 0.00 Cr | 0.39 Cr | 4.69 Cr | 3.92 Cr | 0.30 | 6.76 Cr | 0.0641 |
| 2021-03-31 | 59.63 Cr | 36.70 Cr | 22.93 Cr | 0.3846 | 0.00 Cr | 0.33 Cr | 5.78 Cr | 4.04 Cr | 0.30 | 6.69 Cr | 0.0677 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 55.57 Cr | 256.04 Cr | 61.45 Cr | 186.6868 Cr | 10.22 Cr | -45.35 Cr | 35.94 Cr | 61.83 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 44.5528 Cr |
| 2024-03-31 | 60.23 Cr | 229.99 Cr | 53.52 Cr | 170.3815 Cr | 18.94 Cr | -41.29 Cr | 25.17 Cr | 55.02 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 40.3048 Cr |
| 2023-03-31 | 0.56 Cr | 132.32 Cr | 45.80 Cr | 81.3499 Cr | 1.05 Cr | 0.49 Cr | 15.69 Cr | 67.65 Cr | 11.60 Cr | 0.00 Cr | 0.01 Cr | 29.5130 Cr |
| 2022-03-31 | 7.49 Cr | 68.03 Cr | 24.21 Cr | 43.8152 Cr | 10.12 Cr | 2.63 Cr | 7.74 Cr | 13.70 Cr | 0.16 Cr | 0.00 Cr | 6.83 Cr | 24.2081 Cr |
| 2021-03-31 | 0.19 Cr | 58.90 Cr | 19.19 Cr | 39.7097 Cr | 7.36 Cr | 7.17 Cr | 5.02 Cr | 14.13 Cr | 0.37 Cr | -0.02 Cr | 6.83 Cr | 19.0237 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -4.8338 Cr | -8.7471 Cr | 8.1747 Cr | -13.7806 Cr | 0.0000 Cr | 55.5689 Cr | -8.9468 Cr | 16.1230 Cr | 8.1747 Cr | 0.0000 Cr | -10.7650 Cr |
| 2024-03-31 | -46.6864 Cr | 18.9134 Cr | 73.6838 Cr | -46.6864 Cr | 45.9109 Cr | 60.9750 Cr | 0.0000 Cr | 13.1750 Cr | -3.0717 Cr | 0.0000 Cr | -9.4825 Cr |
| 2023-03-31 | -14.4505 Cr | -0.7652 Cr | 21.3542 Cr | -16.6728 Cr | 6.1384 Cr | 14.4513 Cr | -2.2223 Cr | 6.0112 Cr | -8.0522 Cr | 0.0000 Cr | -7.2358 Cr |
| 2022-03-31 | 6.6361 Cr | -1.2612 Cr | 1.8689 Cr | 6.2464 Cr | 7.2438 Cr | 8.3129 Cr | -0.3897 Cr | 5.2757 Cr | -0.9537 Cr | 0.0000 Cr | -2.7182 Cr |
| 2021-03-31 | -1.4371 Cr | -0.0250 Cr | 1.6186 Cr | -1.5159 Cr | 0.1565 Cr | 1.0691 Cr | -0.0788 Cr | 5.0622 Cr | 2.3621 Cr | 0.0000 Cr | 2.4188 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 40.33 Cr | 34.92 Cr | 5.41 Cr | 0.1342 | 1.47 Cr | 2.32 Cr | 0.11 | 5.85 Cr | 0.0576 |
| 2024-12-31 | 37.71 Cr | 27.68 Cr | 10.03 Cr | 0.2660 | 6.66 Cr | 4.64 Cr | 0.22 | 7.15 Cr | 0.1232 |
| 2024-09-30 | 31.55 Cr | 19.31 Cr | 12.24 Cr | 0.3879 | 7.24 Cr | 4.83 Cr | 0.21 | 7.45 Cr | 0.1530 |
| 2024-06-30 | 28.32 Cr | 20.54 Cr | 7.78 Cr | 0.2746 | 3.78 Cr | 4.66 Cr | 0.21 | 6.69 Cr | 0.1645 |
| 2024-03-31 | 33.50 Cr | 26.02 Cr | 7.49 Cr | 0.2234 | 4.02 Cr | 4.50 Cr | 0.16 | 6.27 Cr | 0.1342 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 55.57 Cr | 0.00 Cr | 55.57 Cr | 14.16 Cr | 35.94 Cr | 181.13 Cr | 61.83 Cr | 256.04 Cr | 61.45 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 52.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -186.49 Cr |
| 2024-09-30 | 52.54 Cr | 0.00 Cr | 52.54 Cr | 0.00 Cr | 40.16 Cr | 176.22 Cr | 64.01 Cr | 244.30 Cr | 57.81 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 60.98 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -176.46 Cr |
| 2024-03-31 | 60.23 Cr | 0.74 Cr | 60.98 Cr | 17.81 Cr | 25.17 Cr | 161.81 Cr | 55.02 Cr | 229.99 Cr | 53.52 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 4.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 5.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 4.66 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 4.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 2.76 Cr | 0.91 Cr | 0.00 Cr | 0.00 Cr | 0.91 Cr | 10.68 Cr | 9.77 Cr | 0.00 Cr | 0.91 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2022-07-21 | July 21, 22 | 131:125 |
| 2009-12-14 | December 14, 09 | 10:1 |
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹804.05 | ₹96,279,696,851.00 | ₹756,659.00 |
Key Executives
Gender: male
Year Born: 1986
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1964
FAQs about Gennex Laboratories Limited
The CEO is Arihant Baid.
The current price is ₹12.16.
The range is ₹11.15-19.
The market capitalization is ₹276.58 crores.
The P/E ratio is 15.60.
The company operates in the Healthcare sector.
Overview of Gennex Laboratories Limited (ISIN: INE509C01026) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹276.58 crores and an average daily volume of 451,286 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.